Data for "Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort Study"

Name: Data for "Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort Study"
Creator: Infectious Diseases Institute, Makerere University; University of Minnesota
Published: 2025-01-01T00:00:00+08:00

Harvard Dataverse2025-05-22 更新2026-04-09 收录

HIV相关隐球菌性脑膜炎

抗真菌疗法真实世界研究

数据链接：

https://dataverse.harvard.edu/citation?persistentId=doi:10.7910/DVN/GGCSJY 数据链接链接失效反馈

官方服务：

资源简介：

In 2022, the World Health Organization (WHO) recommended a single 10 mg/kg dose of liposomal amphotericin B in combination with 14 days of flucytosine and fluconazole (AMBITION-cm regimen) for induction therapy of human immunodeficiency virus (HIV)-associated cryptococcal meningitis, based on the results of the multisite AMBITION-cm trial. We evaluated outcomes after real-world implementation of this novel regimen in Uganda. We enrolled Ugandan adults with cryptococcal meningitis into an observational cohort receiving the AMBITION-cm regimen with therapeutic lumbar punctures in routine care during 2022–2023. We compared 10-week survival and CSF early fungicidal activity with the outcomes observed in the AMBITION-cm clinical trial conducted at the same sites.

提供机构：

Infectious Diseases Institute, Makerere University; University of Minnesota

创建时间：

2025-01-01